“The Filtricine approach is unique. It promises to feed the patients' bodies, not their cancers.”
Dr. Lorenz advises Filtricine on medical strategy and clinical trial design. His expertise spans more than 20 years of drug development and clinical trial design. Previously, he held senior leadership positions at Johnson and Johnson, Cor Therapeutics, Orexigen, Catalyst Biosciences, and Corgentech. Dr. Lorenz earned his MD at Case Western Reserve University.